Hereditary Angioedema Market to be Worth US$3.81 Billion by 2025: Initiatives to Generate Awareness by Physicians and Patient Bodies Drive Growth

ALBANY, New York, August 23, 2017 /PRNewswire/ --

Some of the prominent names operating in the global hereditary angioedema market are Pharming Group NV, Shire plc, CSL Limited, Ionis Pharmaceuticals, Inc., iBio Inc., and BioCryst Pharmaceuticals, Inc. As per a report by Transparency Market Research, the global hereditary angioedema market will likely rise at a healthy 9.1% CAGR between 2017 and 2025 to become worth US$3.81 bn by 2025 from US$ 1.73 bn in 2016.

Browse Market Research Report @ http://www.transparencymarketresearch.com/hereditary-angioedema-market.html

Superior Healthcare Facilities Makes North America Market Leader 

Depending upon the class of drugs, the global hereditary angioedema market can be segmented into C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, and Kallikrein Inhibitor, among others including conventional and pipeline. The C1 esterase inhibitor can be further divided into drugs such as Cinryze, Berinert, and Ruconest. Among them, C1 esterase inhibitor, accounted for more than half the share in the market in 2016 and going forward too, the segment is slated to dominate the market on account of its use in treatment of prophylactic and severe HAE attack. The emergence of novel products will aid the segment to hold on to its leading share in the future.

Geography-wise, North America, Europe, and Rest of the World are the key regions in the global hereditary angioedema market. At present, North America accounts for a leading position and in the upcoming years too is expected to retain its dominant share by rising at a healthy 8.3% CAGR between 2017 and 2025. This is because of the superior healthcare infrastructure and strong support from public and private sector in terms of reimbursements. Increasing knowledge about HAE among patients has resulted better methods of diagnosis of HAE and adoption of specialty drugs for treatment of HAE - this is also expected to catalyze growth in the market.

Inquire for a sample copy of the report @ http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17135

Progress in Diagnosis Catalyzing Growth in Market 

Hereditary angioedema is a rare disease that is estimated to affect 1 in 30,000 to 1 in 50,000 people worldwide. Hereditary angioedema is often mistaken for common allergic reactions and abdominal pain due to lack of awareness both among physicians and patients. It is estimated that around 40% of the affected patient are diagnosed correctly for HAE in the U.S. and Europe. With progress in diagnostic field and different initiatives undertaken by patient bodies and industry players to spread awareness, the market for hereditary angioedema is projected to grow.

"Specialty hereditary angioedema drugs are offered orphan drug designation across the markets which offers them market exclusivity and several incentives in the regional markets. The frequency and severity of HAE attacks is found to be increased with triggers such as stress, anxiety, minor surgeries, hormone replacement therapies and ACE inhibitors used for treatment of hypertension. According to World Allergy Organization, an estimated 40 million people are receiving ACE inhibitor treatment annually. The projected rise in incidences of HAE attacks is estimated to drive growth for global hereditary angioedema market during the forecast period from 2017 to 2025," explains the lead analyst of the TMR report.

Acting as a hindrance to the market, on the other hand, is a few approved specialty hereditary angioedema drugs which makes them highly expensive.

Browse Press Release: http://www.transparencymarketresearch.com/pressrelease/hereditary-angioedema-market.htm

This review is based on the findings of a TMR report, titled, "Hereditary Angioedema Market (Drug Class - C1 Esterase Inhibitor (Cinryze, Berinert, and Ruconest), Selective Bradykinin B2 Receptor Antagonist (Firazyr), and Kallikrein Inhibitor (Kalbitor); Route of Administration - Intravenous, Subcutaneous Injection, and Oral; Distribution Channel - Hospital Pharmacies and Retail Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025."

Global Hereditary Angioedema Market, by Drug Class 

        
        - C1 Esterase Inhibitor
             - Cinryze
             - Berinert
             - Ruconest
        - Selective Bradykinin B2 Receptor Antagonist
             - Firazyr
        - Kallikrein Inhibitor
             - Kalbitor
        - Others
             - Conventional Drugs (attenuated androgens, antifibrinolytic agents
             - Pipeline Products (DX-2930, BCX-7353)

Global Hereditary Angioedema Market, by Route of Administration 

        
        - Intravenous
        - Subcutaneous Injection
        - Oral

Global Hereditary angioedema Market, by Distribution Channel 

        
        - Hospital Pharmacies
        - Retail Pharmacies
        - Others

Global Hereditary Angioedema Market, by Geography 

        
        - North America
        - Europe
        - Rest of the World

Browse Related Research Report: 

Pharmerging Market (Product Type - Pharmaceuticals (Branded Prescription Drugs, Generic Drugs (Branded Generics, Unbranded Generics, and OTC Drugs) and Healthcare (Medical Devices, Diagnostic Instruments, and IT and Record Management); Economic Growth Levels - Tier - 1, Tier - 2, and Tier - 3; Indications - Lifestyle Diseases, Cancer and Autoimmune Diseases, and Infectious Diseases; Distribution Channel - Hospitals, Clinics, Retail Pharmacies, E-commerce, and Drug Stores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

http://www.transparencymarketresearch.com/pharmerging-market.html

Pharmacy Repackaging Systems Market (Product - Blister Card/Compliance Packaging Systems (Multi Dose Blister Card Packaging Systems, Single Dose Blister Card Packaging Systems, Heat Sealers, and Deblisters Machines), Pouch Packaging Automation Systems (Automatic Tablet Packager and Pouch Verification System), Bottle Filling/ Pill Counting Automation Systems (Automated Bottle Filler and Pill Counter), and Liquid Medication Packaging Systems (Oral Liquid Filling Syrup and Automated Vial Filling Pump) ; End User - Retail/Community Pharmacy, Hospital Pharmacy, Long-term Care (LTC) Pharmacies, and Mail Order Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

http://www.transparencymarketresearch.com/pharmacy-repackaging-systems-market.html

Alpha 1 Antitrypsin Deficiency Treatment Market (Treatment Type - Augmentation Therapy, Bronchodilators, Corticosteroids, and Oxygen Therapy; End-user - Hospitals, Specialty Clinics, and Pharmacies; Route of Administration - Parenteral, Inhalation, and Oral) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025 http://www.transparencymarketresearch.com/alpha-1-antitrypsin-deficiency-treatment-market.html

About Us: 

Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

        

        Contact Us: 
        Transparency Market Research 
        90 State Street, Suite 700 
        Albany, NY 12207 
        Tel: +1-518-618-1030 
        USA - Canada Toll Free: 866-552-3453 
        Email: sales@transparencymarketresearch.com  

 

Website: http://www.transparencymarketresearch.com

Blog:https://theglobalhealthnews.com

      http://www.editiontruth.com

SOURCE Transparency Market Research